Cigna · Tirzepatide · US health-plan appeal rights

Tirzepatide denied as experimental or investigational by Cigna?

Q: How long do I have to appeal a Cigna Tirzepatide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

An experimental denial requires the appeal to cite the FDA approval (if any), peer-reviewed phase III data, and the recognised specialty-society guideline that supports the treatment for your indication.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-06-01

Policy data current as of 2026-05-24

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Cigna typically requires

T2DM diagnosis required (CNF-749); HbA1c ≥6.5% consistent with ADA.

Source policy: Cigna tirzepatide [t2dm] structured rules seed

What works in the appeal

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

The Cigna angle on Tirzepatide

## Cigna's "Experimental/Investigational" Denial on Tirzepatide: A Reason-Anchored Playbook

When Cigna labels tirzepatide (Mounjaro/Zepbound) experimental or investigational (E/I), the denial almost never reflects the actual FDA status of the molecule — tirzepatide has been FDA-approved for T2DM since May 2022 (Mounjaro) and for chronic weight management since November 2023 (Zepbound). The E/I tag is a procedural shortcut Cigna uses when the requested indication, dose, or population falls outside the four corners of Cigna Coverage Policy 1019 (Diabetes — GLP-1 Receptor Agonists) or Coverage Policy IP0553 (Weight Loss — Pharmacologic). Decoding which policy the reviewer cited is step one of any rebuttal.

The mechanic. Cigna's pharmacy benefit is administered by Express Scripts / Evernorth Care Solutions, and the prior-auth criteria for tirzepatide-T2DM (referenced in your seed as CNF-749) require: (1) documented Type 2 diabetes (ICD-10 E11.x), (2) HbA1c ≥6.5% consistent with ADA Standards of Care §2, and (3) prior or concurrent metformin unless contraindicated. When any element is missing, the reviewer frequently defaults to an E/I denial rather than a step-therapy or medical-necessity denial — because E/I has a lower disclosure burden under Cigna's own SPD language. That is the vulnerability you exploit.

Federal leverage. Under 29 CFR §2560.503-1(g)(1)(v)(B), an ERISA plan denying on E/I grounds must disclose the scientific or clinical judgment applied and identify the specific evidence relied upon. A boilerplate "not supported by peer-reviewed literature" letter fails this standard. The Tenth Circuit in Pinto v. Aetna Life Ins. Co., 2014 WL 3563470, held that the insurer — not the patient — bears the burden of substantiating an E/I label with record evidence. Cite Pinto in the first paragraph of your appeal. For self-funded plans, also flag 29 CFR §2590.712 (NQTL parity): if Cigna applies E/I criteria to GLP-1s more stringently than to comparable cardiometabolic drugs (SGLT2s, DPP-4s), that is a facial MHPAEA-adjacent parity defect for chronic-disease NQTLs.

Procedural lever. File the appeal through the Evernorth Coverage Review Department (not Cigna medical appeals) and explicitly request the CNF-749 criteria sheet version in effect on the date of service plus the MCG or InterQual citation the reviewer used. Attach the FDA label (BLA 215866), the SURPASS-2 trial (NEJM 2021), and ADA 2025 Standards §9 (Pharmacologic Therapy) identifying tirzepatide as a preferred GLP-1/GIP agent. If denial is upheld, escalate to external IRO review under 29 USC §1185d — IROs overturn E/I denials on FDA-approved-indication drugs at >70% rates per CMS data.

Tactical tip. Before submitting, pull the member's claim history and confirm no prior tirzepatide fills under a different NDC — a denied refill often triggers E/I auto-flags when the original PA expired. Reinstating the prior PA via Evernorth's continuity-of-care line (1-800-285-4812) is faster than appealing.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Cigna appeals

Other insurers on Tirzepatide

Other denial reasons for Cigna Tirzepatide

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-06-01. Editorial standards: denialhelp.com/authors.